{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:45:32Z","timestamp":1785527132553,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Tumor treating fields (TTFields) are FDA-approved for supratentorial glioblastoma, but feasibility in infratentorial tumors remains poorly defined. This simulation study evaluated TTFields dose in brainstem gliomas using patient-specific modeling with scalp-only transducer arrays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MRI and CT imaging from seven patients with brainstem gliomas were used for TTFields planning with MAXPOINT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (Novocure, Switzerland). Clinical target volume (CTV) was defined as enhancing tumor on T1 post-contrast MRI (Gross tumor volume, GTV) plus a 3\u00a0mm peritumoral expansion. The platform optimized scalp-only array layouts, and finite element calculations generated maps of local minimum field intensity (LMiFI, V\/cm) and local minimum power density (LMiPD, mW\/cm\u00b3). Values were compared against a standard, unplanned layout using one-sided paired t-tests, with LMiFI\u2009\u2265\u20091.0\u00a0V\/cm as a therapeutic reference.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MAXPOINT-optimized layouts achieved significantly higher LMiFI than the standard layout across all regions (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.019). GTV median LMiFI was 1.1 vs. 1.0\u00a0V\/cm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019). CTV median LMiFI was 1.1 vs. 1.0\u00a0V\/cm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Brainstem median LMiFI was 1.3 vs. 1.1\u00a0V\/cm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Posterior fossa showed the largest difference: median LMiFI 1.5 vs. 1.2\u00a0V\/cm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). All optimized LMiFI values met or exceeded the therapeutic reference. LMiPD was also significantly higher with MAXPOINT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      across all regions (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.006).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This simulation study demonstrates that patient-specific modeling can achieve favorable TTFields intensities in brainstem gliomas using scalp-only arrays, supporting prospective clinical evaluation for infratentorial tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05697-y","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:51:34Z","timestamp":1783345894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility evaluation of tumor treating fields for brainstem gliomas"],"prefix":"10.1007","volume":"178","author":[{"given":"Anthony Yulin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Urman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Avgeropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Mookerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-3912","authenticated-orcid":false,"given":"Wenyin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"5697_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pan.2013.11.009","volume":"14","author":"M Giladi","year":"2014","unstructured":"Giladi M, Schneiderman RS, Porat Y, Munster M, Itzhaki A, Mordechovich D, Cahal S, Kirson ED, Weinberg U, Palti Y (2014) Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology 14:54\u201363. https:\/\/doi.org\/10.1016\/j.pan.2013.11.009","journal-title":"Pancreatology"},{"key":"5697_CR2","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","volume":"64","author":"ED Kirson","year":"2004","unstructured":"Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y (2004) Disruption of cancer cell replication by alternating electric fields. Cancer Res 64:3288\u20133295","journal-title":"Cancer Res"},{"key":"5697_CR3","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 318:2306\u20132316. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"JAMA"},{"key":"5697_CR4","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (2012) NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192\u20132202. https:\/\/doi.org\/10.1016\/j.ejca.2012.04.011","journal-title":"Eur J Cancer"},{"key":"5697_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11060-020-03655-w","volume":"151","author":"B Wummer","year":"2021","unstructured":"Wummer B, Woodworth D, Flores C (2021) Brain stem gliomas and current landscape. J Neurooncol 151:21\u201328. https:\/\/doi.org\/10.1007\/s11060-020-03655-w","journal-title":"J Neurooncol"},{"key":"5697_CR6","doi-asserted-by":"publisher","unstructured":"Guillamo JS, Monjour A, Taillandier L, Devaux B, Varlet P, Haie-Meder C, Defer GL, Maison P, Mazeron JJ, Cornu P, Delattre JY (2001) Association des Neuro-Oncologues d\u2019Expression F Brainstem gliomas in adults: prognostic factors and classification. Brain 124: 2528\u20132539 https:\/\/doi.org\/10.1093\/brain\/124.12.2528","DOI":"10.1093\/brain\/124.12.2528"},{"key":"5697_CR7","doi-asserted-by":"publisher","unstructured":"Lo Greco MC, Marano G, La Rocca M, Acquaviva G, Milazzotto R, Liardo RLE, Basile A, Foti PV, Palmucci S, David E, Parisi S, Pontoriero A, Pergolizzi S, Spatola C (2025) Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review. Cancers (Basel) 17. https:\/\/doi.org\/10.3390\/cancers17030420","DOI":"10.3390\/cancers17030420"},{"key":"5697_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11060-020-03406-x","volume":"147","author":"E Lok","year":"2020","unstructured":"Lok E, San P, Liang O, White V, Wong ET (2020) Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma. J Neurooncol 147:125\u2013133. https:\/\/doi.org\/10.1007\/s11060-020-03406-x","journal-title":"J Neurooncol"},{"key":"5697_CR9","doi-asserted-by":"publisher","unstructured":"Ramirez-Fort MK, Naveh A, McClelland S 3rd, Gilman CK, Fort M, Mendez M, Matta J, Bomzon Z, Lange CS (2021) Computational simulations establish a novel transducer array placement arrangement that extends delivery of therapeutic TTFields to the infratentorium of patients with brainstem gliomas. Rep Pract Oncol Radiother 26:1045\u20131050. https:\/\/doi.org\/10.5603\/RPOR.a2021.0132","DOI":"10.5603\/RPOR.a2021.0132"},{"key":"5697_CR10","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.1073\/pnas.0702916104","volume":"104","author":"ED Kirson","year":"2007","unstructured":"Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y (2007) Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 104:10152\u201310157. https:\/\/doi.org\/10.1073\/pnas.0702916104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5697_CR11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.04.008","volume":"104","author":"MT Ballo","year":"2019","unstructured":"Ballo MT, Urman N, Lavy-Shahaf G, Grewal J, Bomzon Z, Toms S (2019) Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial. Int J Radiat Oncol Biol Phys 104:1106\u20131113. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.04.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5697_CR12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41598-023-28769-9","volume":"13","author":"DJ Segar","year":"2023","unstructured":"Segar DJ, Bernstock JD, Arnaout O, Bi WL, Friedman GK, Langer R, Traverso G, Rampersad SM (2023) Modeling of intracranial tumor treating fields for the treatment of complex high-grade gliomas. Sci Rep 13:1636. https:\/\/doi.org\/10.1038\/s41598-023-28769-9","journal-title":"Sci Rep"},{"key":"5697_CR13","doi-asserted-by":"publisher","first-page":"vdae032","DOI":"10.1093\/noajnl\/vdae032","volume":"6","author":"N Mikic","year":"2024","unstructured":"Mikic N, Gentilal N, Cao F, Lok E, Wong ET, Ballo M, Glas M, Miranda PC, Thielscher A, Korshoej AR (2024) Tumor-treating fields dosimetry in glioblastoma: Insights into treatment planning, optimization, and dose-response relationships. Neurooncol Adv 6:vdae032. https:\/\/doi.org\/10.1093\/noajnl\/vdae032","journal-title":"Neurooncol Adv"},{"key":"5697_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/neuonc\/noae267","volume":"27","author":"LB Nabors","year":"2025","unstructured":"Nabors LB, Hattangadi-Gluth J, Horbinski C, Portnow J (2025) NCCN CNS Tumor Guidelines Update for 2024. Neuro Oncol 27:595\u2013596. https:\/\/doi.org\/10.1093\/neuonc\/noae267","journal-title":"Neuro Oncol"},{"key":"5697_CR15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3389\/fneur.2019.01026","volume":"10","author":"J Onken","year":"2019","unstructured":"Onken J, Goerling U, Heinrich M, Pleissner S, Krex D, Vajkoczy P, Misch M (2019) Patient Reported Outcome (PRO) Among High-Grade Glioma Patients Receiving TTFields Treatment: A Two Center Observational Study. Front Neurol 10:1026. https:\/\/doi.org\/10.3389\/fneur.2019.01026","journal-title":"Front Neurol"},{"key":"5697_CR16","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3389\/fonc.2020.01045","volume":"10","author":"ME Lacouture","year":"2020","unstructured":"Lacouture ME, Anadkat MJ, Ballo MT, Iwamoto F, Jeyapalan SA, La Rocca RV, Schwartz M, Serventi JN, Glas M (2020) Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. Front Oncol 10:1045. https:\/\/doi.org\/10.3389\/fonc.2020.01045","journal-title":"Front Oncol"},{"key":"5697_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","volume":"141","author":"SA Toms","year":"2019","unstructured":"Toms SA, Kim CY, Nicholas G, Ram Z (2019) Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol 141:467\u2013473. https:\/\/doi.org\/10.1007\/s11060-018-03057-z","journal-title":"J Neurooncol"},{"key":"5697_CR18","doi-asserted-by":"publisher","first-page":"1430793","DOI":"10.3389\/fonc.2024.1430793","volume":"14","author":"C Jelgersma","year":"2024","unstructured":"Jelgersma C, Alsolivany J, Akkas G, Wasilewski D, Gastl B, Misch M, Capper D, Kaul D, Bullinger L, Vajkoczy P, Onken J (2024) Real-world experience with TTFields in glioma patients with emphasis on therapy usage. Front Oncol 14:1430793. https:\/\/doi.org\/10.3389\/fonc.2024.1430793","journal-title":"Front Oncol"},{"key":"5697_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","volume":"4","author":"MJB Taphoorn","year":"2018","unstructured":"Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R (2018) Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 4:495\u2013504. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5082","journal-title":"JAMA Oncol"},{"key":"5697_CR20","doi-asserted-by":"publisher","unstructured":"Mrugala MM, Shi W, Iwomoto F, Lukas RV, Palmer JD, Suh JH, Glas M (2024) Global post marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011\u20132022. J Neurooncol 169:25\u201338. https:\/\/doi.org\/10.1007\/s11060-024-04682-721","DOI":"10.1007\/s11060-024-04682-721"},{"key":"5697_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11060-013-1312-2","volume":"116","author":"G Reyes-Botero","year":"2014","unstructured":"Reyes-Botero G, Giry M, Mokhtari K, Labussiere M, Idbaih A, Delattre JY, Laigle-Donadey F, Sanson M (2014) Molecular analysis of diffuse intrinsic brainstem gliomas in adults. J Neurooncol 116:405\u2013411. https:\/\/doi.org\/10.1007\/s11060-013-1312-2","journal-title":"J Neurooncol"},{"key":"5697_CR22","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41467-020-16682-y","volume":"11","author":"LH Chen","year":"2020","unstructured":"Chen LH, Pan C, Diplas BH, Xu C, Hansen LJ, Wu Y, Chen X, Geng Y, Sun T, Sun Y, Zhang P, Wu Z, Zhang J, Li D, Zhang Y, Wu W, Wang Y, Li G, Yang J, Wang X, Xu C, Wang S, Waitkus MS, He Y, McLendon RE, Ashley DM, Yan H, Zhang L (2020) The integrated genomic and epigenomic landscape of brainstem glioma. Nat Commun 11:3077. https:\/\/doi.org\/10.1038\/s41467-020-16682-y","journal-title":"Nat Commun"},{"key":"5697_CR23","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1109\/TBME.2020.2983653","volume":"67","author":"ST Lang","year":"2020","unstructured":"Lang ST, Gan LS, McLennan C, Monchi O, Kelly JJP (2020) Impact of Peritumoral Edema During Tumor Treatment Field Therapy: A Computational Modelling Study. IEEE Trans Biomed Eng 67:3327\u20133338. https:\/\/doi.org\/10.1109\/TBME.2020.2983653","journal-title":"IEEE Trans Biomed Eng"},{"key":"5697_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","volume":"24","author":"T Leal","year":"2023","unstructured":"Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo M, Roubec J, Petruzelka L, Havel L, Kalmadi S, Ward J, Andric Z, Berghmans T, Gerber DE, Kloecker G, Panikkar R, Aerts J, Delmonte A, Pless M, Greil R, Rolfo C, Akerley W, Eaton M, Iqbal M, Langer C, Investigators LS (2023) Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol 24:1002\u20131017. https:\/\/doi.org\/10.1016\/S1470-2045(23)00344-3","journal-title":"Lancet Oncol"},{"key":"5697_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijrobp.2025.08.066","volume":"124","author":"MP Mehta","year":"2026","unstructured":"Mehta MP, Gondi V, Ahluwalia MS, Roberge D, Sio TTW, Trifiletti DM, Muanza T, Krpan AM, Zhu Z, Ramakrishna NR, Fiveash JB, Metellus P, Yu J, Wang CJ, Jacob J, Freyschlag CF, Csoszi T, Salmaggi A, Taliansky A, Lucas A, Debus J, Brown PD, Harat M (2026) Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study. Int J Radiat Oncol Biol Phys 124:278\u2013293. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.08.066","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5697_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/children13010084","volume":"13","author":"A Makimoto","year":"2026","unstructured":"Makimoto A, Terashima K, Nishikawa R, Fujisaki H, Kurihara J, Ihara S, Adachi JI, Enokizono M, Mori N, Morikawa Y, Yuza Y (2026) Safety and Efficacy of Tumor-Treating Fields (TTFields) Therapy for Pediatric High-Grade Glioma: Results of a Prespecified Interim Analysis of the First Three Cases. Child (Basel) 13:84. https:\/\/doi.org\/10.3390\/children13010084","journal-title":"Child (Basel)"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05697-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05697-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05697-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:09:06Z","timestamp":1785521346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05697-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5697"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05697-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by Thomas Jefferson University\u2019s Institutional Review Board. Informed consent for accrual was waived due to its retrospective nature.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wenyin Shi received consultation fee from Novocure, Brainlab, Varian.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"91"}}